Biotech · Private company
Pierre Fabre Medicament
Track this companyFree. Adds Pierre Fabre Medicament to your Dealase workspace and tells you when its record changes.
Clinical trials97 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline14
- tabelecleucelPhase 3 · Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)ClinicalTrials.gov · fetched Nov 12, 2026
- BinimetinibPhase 2 · BRAF V600E-mutant Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 2 · BRAF V600E-mutant Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- encorafenibPhase 2 · BRAF V600E-mutant Metastatic Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- STX-241Phase 2 · Non-small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- STX-721/PFL-721 (3 dose levels)Phase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- STX-721/PFL-721 (Escalated)Phase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- STX-721/PFL-721 (Escalated) with platinum-based chemotherapyPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- STX-721/PFL-721 (RP2D)Phase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- STX-721/PFL-721 with platinum-based chemotherapyPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- TabelecleucelPhase 2 · Epstein-Barr Virus (EBV)-Associated DiseasesClinicalTrials.gov · fetched Nov 12, 2026
- VERT-002Phase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- KIN-2787Phase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- KIN-2787 and binimetinibPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET AlterationsPHASE1_PHASE2 · RECRUITING · started Oct 22, 2024ClinicalTrials.gov NCT06669117 · fetched Nov 12, 2026
- Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIsPHASE1_PHASE2 · RECRUITING · started Sep 17, 2024ClinicalTrials.gov NCT06567015 · fetched Nov 12, 2026
- First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion MutationsPHASE1_PHASE2 · RECRUITING · started Sep 26, 2023ClinicalTrials.gov NCT06043817 · fetched Nov 12, 2026
- Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal DysplasiaPHASE2 · RECRUITING · started Apr 26, 2022ClinicalTrials.gov NCT04980638 · fetched Nov 12, 2026
- A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsPHASE1 · RECRUITING · started Aug 4, 2021ClinicalTrials.gov NCT04913285 · fetched Nov 12, 2026
- A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated DiseasesPHASE2 · ACTIVE_NOT_RECRUITING · started Jul 14, 2021ClinicalTrials.gov NCT04554914 · fetched Nov 12, 2026
- Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal CancerPHASE2 · COMPLETED · started Jan 17, 2019ClinicalTrials.gov NCT03693170 · fetched Nov 12, 2026
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyPHASE3 · RECRUITING · started Dec 29, 2017ClinicalTrials.gov NCT03394365 · fetched Nov 12, 2026
- Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerPHASE3 · COMPLETED · started Oct 13, 2016ClinicalTrials.gov NCT02928224 · fetched Nov 12, 2026